绝经前HR阳性/HER2阴性乳腺癌辅助治疗的不确定性与证据缺口
该综述聚焦绝经前激素受体阳性/HER2阴性早期乳腺癌这一独特人群,梳理辅助内分泌治疗、CDK4/6抑制剂、卵巢功能抑制、基因组检测及依从性等领域的现有证据与不确定性,并提出个体化治疗的实用临床框架。
要点
- 绝经前HR阳性/HER2阴性乳腺癌生物学更具侵袭性,治疗决策复杂。
- 辅助内分泌治疗仍是基石,高危患者可加用CDK4/6抑制剂。
- 卵巢功能抑制、基因组检测指导化疗、延长内分泌治疗等存在不确定性。
核心结论
- 绝经前HR阳性/HER2阴性早期乳腺癌管理仍具挑战,数据异质且多外推自绝经后人群。
研究设计与样本
- 综述整合专门试验与亚组分析证据,覆盖辅助内分泌治疗、CDK4/6抑制剂、卵巢功能抑制、基因组检测、依从性及生存期问题。
主要发现
- 辅助内分泌治疗联合选择性CDK4/6抑制剂是治疗基石,但卵巢功能抑制最佳使用、基因组检测指导化疗、延长内分泌治疗候选者选择等存在重大不确定性。
临床怎么用
- 提出实用临床框架以支持个体化治疗策略并优化该人群的当代治疗格局下的照护。
局限性
- 现有数据异质、不断演变,且常从以绝经后女性为主的人群外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer represent a clinically distinct population, characterized by more aggressive tumor biology, unique survivorship concerns, and complex treatment decision making. Although evidence from dedicated trials and subgroup analyses is available, management remains challenging because data are heterogeneous, evolving, and often extrapolated from broader populations that include predominantly postmenopausal women. Adjuvant endocrine therapy (ET), with the addition of cyclin-dependent kinase 4/6 inhibitors in selected higher-risk patients, remains the cornerstone of treatment; however, major uncertainties persist regarding the optimal use of ovarian function suppression, the interpretation of genomic assays to inform chemotherapy decisions, the selection of candidates for extended ET, and the management of adherence, treatment-related toxicities, pregnancy-related issues, and survivorship concerns. In this review, we synthesize current evidence across these domains and propose a pragmatic clinical framework to support individualized treatment strategies and optimize care for this population in the contemporary therapeutic landscape.
引用
- Licata L, Mariani M, Chiavassa A, et al. Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR-positive/HER2-negative breast cancer. Ann Oncol. 2026. PMID: 42754095. doi:10.1016/j.annonc.2026.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。